Table 2. DUX4 mRNA expression in FSHD and control cell lines.
Cell Code | Status | Haplotypes | Cell type A | DUX4-fl | DUX4-s | 3-prime |
MB73 | FSHD | A161(8)B/161C | MB | X | X | X |
MB183 | FSHD | A161(5)/B163 | MB | X | O | X |
MB148 | FSHD | A161(3)/A161 | MB | X | O | X |
MB200 | FSHD2 | A161(14)/B168 | MB | X | XS | X |
MB216 | FSHD | A161(6)/A168 | MB | O | O | O |
MB219 | FSHD | A161(5)/B168 | MB | O | O | O |
MB230 | contr | A161/163A | MB | O | X | O |
MB196 | contr | A161/163A | MB | O | X | O |
MB226 | contr | A161/A161 | MB | O | X | O |
MB135 | contr | A161/B163 | MB | O | XS | O |
MB73 | FSHD | A161/161 | MT | X | X | XS |
MB183 | FSHD | A161/B163 | MT | X | O | X |
MB148 | FSHD | A161/A161 | MT | X | O | XS |
MB200 | FSHD2 | A161/B168 | MT | XS | O | XS |
MB216 | FSHD | A161/A168 | MT | X | O | XS |
MB219 | FSHD | A161/B168 | MT | X | O | X |
MB230 | contr | A161/163A | MT | O | X | O |
MB196 | contr | A161/163A | MT | O | X | O |
MB226 | contr | A161/A161 | MT | O | X | O |
MB135 | contr | A161/B163 | MT | O | X | O |
M83-9 | contr | A161/168A | fibro | O | XS | O |
M83-9 | contr | iPS | XS | O | X | |
M83-9 | contr | EB | O | X | O | |
43-1 | FSHD | A161(5)/A161 | fibro | XS | O | O |
43-1 | FSHD | iPS | XS | O | X | |
43-1 | FSHD | EB | X | O | XS | |
83-6 | FSHD | A161(7)/B168 | fibro | XS | XS | X |
83-6 | FSHD | iPS | X | O | X | |
83-6 | FSHD | EB | X | O | XS |
MB, myoblasts; MT, myotubes; fibro, fibroblasts; iPS, induced pleuripotent stem cells, EB, embryoid bodies.
Number of repeats on contracted allele, if known.
Assignment of the second 4q allele variant is incomplete.
n.d., not tested; X, product present; XS, product sequenced; O, product absent.